SCHEMBL7038412

SCHEMBL7038412

Nc1nc(Br)nc2c1ncn2[C@@H]1O[C@H](CO)C(O)C1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.75
NT5E P21589 1/20 0.75
HIF1A Q16665 1/20 0.75
ADORA2A P29274 7/20 0.73
ADORA2B P29275 5/20 0.73
ADORA3 P0DMS8 3/20 0.71
ADORA1 P30542 2/20 0.69
DPP4 P27487 1/20 0.69
MEN1 O00255 1/20 0.69
SLC28A1 O00337 1/20 0.69
MAP3K7 O43318 1/20 0.69
SLC28A2 O43868 1/20 0.69
GAPDH P04406 1/20 0.69
MAPK1 P28482 1/20 0.69
STAT6 P42226 1/20 0.69
PI4KA P42356 1/20 0.69
KMT2A Q03164 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
PI4K2B Q8TCG2 1/20 0.69
DOT1L Q8TEK3 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7038406 1.00 LMNA (0.75) LMNANT5EHIF1AADORA2AADORA2B
Phosphoric Acid SCHEMBL21465159 0.94 LMNA (0.68) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL8333120 0.91 LMNA (0.61) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL8333122 0.91 LMNA (0.61) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL8923023 0.90 ADORA2A (0.77) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL8923008 0.90 ADORA2A (0.77) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL24359132 0.88 LMNA (0.78) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL16579288 0.88 LMNA (0.78) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL10176676 0.88 LMNA (0.78) LMNANT5EHIF1AADORA2AADORA2B
SCHEMBL22559823 0.88 LMNA (0.78) LMNANT5EHIF1AADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0763049-B1 NUCLEOSIDE MONOPHOSPHATE DERIVATIVES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS HEIDELBERG PHARMA HOLDING GMBH (DE) 2003-04-02 EP claimed
US-6025343-A Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs ROCHE DIAGNOSTICS GMBH (DE) 2000-02-15 US claimed
EP-0763049-A1 NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS Roche Diagnostics GmbH (DE) 1997-03-19 EP claimed
WO-1995032984-A1 NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS BOEHRINGER MANNHEIM GMBH (DE) 1995-12-07 WO claimed
JP-54061195-A None JP disclosed
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 EP disclosed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 WO disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 WO disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 US disclosed
WO-1995032984-A1 NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS BOEHRINGER MANNHEIM GMBH (DE) 1995-12-07 WO disclosed
WO-1994006438-A1 ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-03-31 WO disclosed
EP-0253962-B1 USE OF ADENOSINE DERIVATIVES AS ANTI-DEMENTIA AGENTS HOECHST JAPAN LIMITED (JP) 1993-03-24 EP disclosed
US-5023244-A Anti-dementia agents HOECHST JAPAN LIMITED (JP) 1991-06-11 US disclosed
EP-0253962-A2 Use of adenosine derivatives as anti-dementia agents HOECHST JAPAN LIMITED (JP) 1988-01-27 EP disclosed
US-4225591-A CORONARY VASODILATOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-09-30 US disclosed
JP-S5461195-A N2-SUBSTITUTED PHENYL-2,6-DIAMINONEBULARIN TAKEDA CHEM IND LTD 1979-05-17 JP disclosed
US-3936439-A VASODILATION, ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 LMNA 616/4885NT5E 1006/4885HIF1A 4525/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 LMNA 1182/4885NT5E 2810/4885HIF1A 4336/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT LMNA 1904/4885NT5E 1935/4885HIF1A 4457/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 LMNA 3144/4885NT5E 469/4885HIF1A 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.